We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+24.07%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$163M
AUM Growth
–
Cap. Flow
+$196M
Cap. Flow
% of AUM
120.52%
Top 10 Holdings %
Top 10 Hldgs %
40.87%
Holding
62
New
62
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Gilead Sciences
GILD
|
+$9.4M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$5.09M |
| 3 |
Biogen
BIIB
|
+$4.14M |
| 4 |
SPNC
Spectranetics Corp
SPNC
|
+$3.75M |
| 5 |
Accuray
ARAY
|
+$3.49M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 50.1% |
| 2 | Technology | 0.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
CALL
DELISTED
Allergan Inc
AGN
| $11.1M | 6.83% |
+100,000
| New | +$9.55M |
|
|
2
Gilead Sciences
GILD
$167B
| $10.1M | 6.24% |
+135,000
| New | +$9.4M |
|
|
3
CALL
Gilead Sciences
GILD
$167B
| $7.51M | 4.62% |
+100,000
| New | +$6.96M |
|
4
CALL
Edwards Lifesciences
EW
$49.4B
| $6.58M | 4.05% |
+600,000
| New | +$6.76M |
|
|
NUVA
5
CALL
DELISTED
NuVasive, Inc.
NUVA
| $6.47M | 3.98% |
+200,000
| New | +$6.01M |
|
|
6
PUT
Gilead Sciences
GILD
$167B
| $5.63M | 3.47% |
+750,000
| New | +$52.2M |
|
|
7
Bristol-Myers Squibb
BMY
$124B
| $5.32M | 3.27% |
+100,000
| New | +$5.09M |
|
8
CALL
Vertex Pharmaceuticals
VRTX
$123B
| $4.83M | 2.97% |
+65,000
| New | +$4.53M |
|
|
9
Biogen
BIIB
$30.4B
| $4.47M | 2.75% |
+16,000
| New | +$4.14M |
|
|
SPNC
10
DELISTED
Spectranetics Corp
SPNC
| $4.38M | 2.69% |
+175,000
| New | +$3.75M |
|
11
CALL
Teva Pharmaceuticals
TEVA
$37.3B
| $4.01M | 2.47% |
+100,000
| New | +$3.94M |
|
|
12
Accuray
ARAY
$30.8M
| $3.92M | 2.41% |
+450,000
| New | +$3.49M |
|
|
THOR
13
CALL
DELISTED
THORATEC CORPORATION
THOR
| $3.66M | 2.25% |
+100,000
| New | +$3.92M |
|
14
Prothena Corp
PRTA
$453M
| $3.45M | 2.12% |
+130,000
| New | +$3.26M |
|
|
CBST
15
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $3.44M | 2.12% |
+50,000
| New | +$3.24M |
|
|
MZOR
16
DELISTED
Mazor Robotics Ltd.
MZOR
| $3.42M | 2.1% |
+175,000
| New | +$3.21M |
|
17
Insmed
INSM
$23.5B
| $3.4M | 2.09% |
+200,000
| New | +$3.06M |
|
|
DYAX
18
DELISTED
DYAX CORPORATION
DYAX
| $3.39M | 2.09% |
+450,000
| New | +$3.42M |
|
|
HTWR
19
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
| $3.34M | 2.06% |
+35,600
| New | +$3.01M |
|
20
Zimmer Biomet
ZBH
$17.6B
| $3.26M | 2.01% |
+36,050
| New | +$3.12M |
|
21
Arrowhead Research
ARWR
$10.5B
| $2.98M | 1.84% |
+275,000
| New | +$2.2M |
|
22
Community Health Systems
CYH
$465M
| $2.75M | 1.69% |
+84,700
| New | +$2.91M |
|
23
QuidelOrtho
QDEL
$1.19B
| $2.63M | 1.62% |
+85,000
| New | +$2.18M |
|
24
Puma Biotechnology
PBYI
$434M
| $2.59M | 1.59% |
+25,000
| New | +$1.47M |
|
|
ACGN
25
DELISTED
Aceragen Inc
ACGN
| $2.55M | 1.57% |
+4,048
| New | +$1.35M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q4 2013 Portfolio in Review
Q4 2013 is the first quarter with a 13F filing on record for Ghost Tree Capital, which disclosed 62 positions worth $163M. Its ten largest holdings account for 41% of the portfolio.
Its largest position is Gilead Sciences: 135,000 shares worth $10.1M.
By sector, the portfolio is most concentrated in Healthcare at 50% of assets, followed by Technology.
- Ghost Tree Capital's largest Q4 2013 buy was Gilead Sciences: 135,000 shares worth $10.1M.
- Ghost Tree Capital's ten largest holdings make up 41% of its $163M portfolio in Q4 2013.
- Ghost Tree Capital disclosed 62 positions in Q4 2013, its first 13F filing on record.
Based on Ghost Tree Capital's 13F filing for Q4 2013, filed 14 Feb 2014.